These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

We have written at length about the U.S. Food and Drug Administration’s (FDA’s) actions to promulgate regulations specifying the agency’s authority ...

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...

In a recently published Perspective article in the New England Journal of Medicine, Marisha Burden, MD, MBA, and Liselotte ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

One in six patients in phase II oncology clinical trials received a treatment that was eventually approved by the FDA, according to a longitudinal study. In a sample of 400 phase II trials that ...

Renowned for its tailored and scalable solutions, and with facilities which include a purpose-built MHRA Accredited Phase I Unit in the UK, the organization specializes in Clinical Pharmacology ...

The primary purpose of the Phase 2 part of the EBO-301 study was ... Using QOL-B as a continuous measure of clinical improvement, epetraborole showed nominal statistical superiority versus placebo ...